MCID: BRS045
MIFTS: 29

Breast Adenoma malady

Categories: Cancer diseases

Aliases & Classifications for Breast Adenoma

Aliases & Descriptions for Breast Adenoma:

Name: Breast Adenoma 12 14 69
Ademoma - Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1625
NCIt 47 C40382
SNOMED-CT 64 269640007
UMLS 69 C1328385

Summaries for Breast Adenoma

MalaCards based summary : Breast Adenoma, also known as ademoma - breast, is related to childhood brain germinoma and adenoma. An important gene associated with Breast Adenoma is OSMR (Oncostatin M Receptor), and among its related pathways/superpathways are MicroRNAs in cancer and Hepatitis C and Hepatocellular Carcinoma. The drugs Sulindac and Exenatide have been mentioned in the context of this disorder. Affiliated tissues include breast and skin, and related phenotypes are Decreased Salmonella enterica Typhimurium effector injection and Decreased Salmonella enterica Typhimurium membrane closure

Related Diseases for Breast Adenoma

Diseases related to Breast Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 childhood brain germinoma 10.1 CD44 MYC
2 adenoma 9.9
3 sertoli-leydig cell tumor 9.5
4 skin papilloma 9.5
5 papilloma 9.5
6 leydig cell tumor 9.5
7 breast myofibroblastoma 8.4 CD44 H2AFX ING3 MXI1 MYC ODC1

Graphical network of the top 20 diseases related to Breast Adenoma:



Diseases related to Breast Adenoma

Symptoms & Phenotypes for Breast Adenoma

GenomeRNAi Phenotypes related to Breast Adenoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased Salmonella enterica Typhimurium effector injection GR00133-A-4 8.96 MYC ODC1
2 Decreased Salmonella enterica Typhimurium membrane closure GR00133-A-6 8.62 MYC ODC1

MGI Mouse Phenotypes related to Breast Adenoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.7 CD44 H2AFX MXI1 MYC ODC1 PAK4
2 growth/size/body region MP:0005378 9.5 CD44 H2AFX MYC ODC1 OSMR PAK4
3 mortality/aging MP:0010768 9.23 CD44 H2AFX MXI1 MYC ODC1 PAK4

Drugs & Therapeutics for Breast Adenoma

Drugs for Breast Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sulindac Approved Phase 3 38194-50-2 5352 1548887
2
Exenatide Approved, Investigational Phase 2, Phase 3 141758-74-9 15991534
3
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
4
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
5
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
6
Pembrolizumab Approved Phase 3,Phase 1,Phase 2 1374853-91-4
7
Cholecalciferol Approved, Nutraceutical Phase 3 67-97-0 6221 10883523 5280795
8
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
9 Bone Density Conservation Agents Phase 3
10 Calcium, Dietary Phase 3
11 Ergocalciferols Phase 3
12 Micronutrients Phase 3,Phase 1
13 Trace Elements Phase 3,Phase 1
14 vitamin d Phase 3
15 Vitamins Phase 3,Phase 1
16 Anti-Infective Agents Phase 3,Phase 2,Phase 1
17 Antirheumatic Agents Phase 3,Phase 2,Phase 1
18 Hormones Phase 2, Phase 3,Phase 1
19 Antimitotic Agents Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
21 Antiviral Agents Phase 3,Phase 2,Phase 1
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
23 Analgesics Phase 3
24 Analgesics, Non-Narcotic Phase 3
25 Anti-Inflammatory Agents Phase 3
26 Anti-Inflammatory Agents, Non-Steroidal Phase 3
27 Antiparasitic Agents Phase 3
28 Antiprotozoal Agents Phase 3
29 Cyclooxygenase Inhibitors Phase 3
30 Peripheral Nervous System Agents Phase 3
31 Hormone Antagonists Phase 2, Phase 3,Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
33 Hypoglycemic Agents Phase 2, Phase 3
34 Incretins Phase 2, Phase 3
35 Antimetabolites Phase 3,Phase 2
36 Antimetabolites, Antineoplastic Phase 3,Phase 2
37 Vinca Alkaloids Phase 3,Phase 2
38 Antibodies Phase 3,Phase 1,Phase 2
39 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
40 Immunoglobulins Phase 3,Phase 1,Phase 2
41 Anticholesteremic Agents Phase 3
42 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
43 Hypolipidemic Agents Phase 3
44 Lipid Regulating Agents Phase 3
45 Rosuvastatin Calcium Phase 3 147098-20-2
46 Cola Nutraceutical Phase 3,Phase 2,Phase 1
47 Calciferol Nutraceutical Phase 3
48 Vitamin D2 Nutraceutical Phase 3
49
Ornithine Nutraceutical Phase 3 3184-13-2 6262 389
50
Megestrol acetate Approved, Vet_approved Phase 1, Phase 2 595-33-5 11683

Interventional clinical trials:

(show all 38)
id Name Status NCT ID Phase
1 Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women Completed NCT01052051 Phase 3
2 S0820, Adenoma and Second Primary Prevention Trial Recruiting NCT01349881 Phase 3
3 New Imaging Procedure for the Localisation of Insulinoma and Transplanted Islet Cells Recruiting NCT02127541 Phase 2, Phase 3
4 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Not yet recruiting NCT02991482 Phase 3
5 Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Terminated NCT01011478 Phase 3
6 High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma Unknown status NCT00002465 Phase 1, Phase 2
7 Dendritic Cell Vaccination for Patients With Solid Tumors Unknown status NCT01291420 Phase 1, Phase 2
8 Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer Completed NCT00002475 Phase 2
9 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Recruiting NCT00939523 Phase 2
10 Vinorelbine in Mesothelioma Recruiting NCT02139904 Phase 2
11 Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma Recruiting NCT02611037 Phase 2
12 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Recruiting NCT02893930 Phase 2
13 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2
14 18F-FSPG PET/CT for Cancer Patients on Therapy Suspended NCT02599194 Phase 2
15 Mithramycin for Lung, Esophagus, and Other Chest Cancers Suspended NCT01624090 Phase 2
16 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2
17 A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients Withdrawn NCT02661100 Phase 1, Phase 2
18 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
19 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
20 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
21 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
22 Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Completed NCT00423254 Phase 1
23 Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors Completed NCT00703638 Phase 1
24 A Study of LY3023414 in Participants With Advanced Cancer Recruiting NCT01655225 Phase 1
25 Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Recruiting NCT02071862 Phase 1
26 Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso Recruiting NCT02580747 Phase 1
27 Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Recruiting NCT02414269 Phase 1
28 Safety Study of MGD009 in B7-H3-expressing Tumors Recruiting NCT02628535 Phase 1
29 Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion Active, not recruiting NCT01997190 Phase 1
30 Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Withdrawn NCT02567396 Phase 1
31 Open Versus Video-Assisted Minimal-Invasive Parathyroid Surgery Completed NCT00877981
32 A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Completed NCT00428220
33 B-Receptor Signaling in Cardiomyopathy Completed NCT01135849
34 Everolimus TDM to Predict Long Term Toxicity Recruiting NCT03033186
35 Familial Investigations of Childhood Cancer Predisposition Recruiting NCT03050268
36 Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program Recruiting NCT02585362
37 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
38 Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer Active, not recruiting NCT00372840

Search NIH Clinical Center for Breast Adenoma

Genetic Tests for Breast Adenoma

Anatomical Context for Breast Adenoma

MalaCards organs/tissues related to Breast Adenoma:

39
Breast, Skin

Publications for Breast Adenoma

Articles related to Breast Adenoma:

id Title Authors Year
1
Radio-sensitization by Piper longumine of human breast adenoma MDA-MB-231 cells in vitro. ( 24815473 )
2014
2
Ectopic breast adenoma of the anal margin: an atypical presentation of anorectal pain. ( 23229560 )
2013
3
Mutation of p53 in skin papilloma and tubular breast adenoma of albino mice. ( 16624193 )
2006
4
Immunohistochemical analysis of the distribution of the human ATPase (hASNA-I) in normal tissues and its overexpression in breast adenomas and carcinomas. ( 9774623 )
1998
5
Ollier's disease associated with ovarian Sertoli-Leydig cell tumor and breast adenoma. ( 2029079 )
1991

Variations for Breast Adenoma

Expression for Breast Adenoma

Search GEO for disease gene expression data for Breast Adenoma.

Pathways for Breast Adenoma

Pathways related to Breast Adenoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.81 CD44 MYC PAK4
2 10.66 CD44 MYC
3 10.32 H2AFX MYC

GO Terms for Breast Adenoma

Biological processes related to Breast Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 liver regeneration GO:0097421 9.16 MYC SRSF1
2 cellular response to fibroblast growth factor stimulus GO:0044344 8.96 CD44 MYC
3 positive regulation of cell proliferation GO:0008284 8.92 MYC ODC1 OSMR PTH1R

Molecular functions related to Breast Adenoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine receptor activity GO:0004896 8.62 CD44 OSMR

Sources for Breast Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....